Amgen CFO receives 12,063-share stock award

Amgen Inc. executive vice president and CFO Peter H. Griffith reported an equity award of 12,063 shares of common stock on a Form 4.

Rhea-AI Filing Summary

Amgen Inc. executive vice president and CFO Peter H. Griffith reported an equity award of 12,063 shares of common stock on a Form 4. The shares were acquired as a grant at no cash cost, increasing his directly held stake to 54,587 shares.

The reported holdings include 676 dividend equivalent units granted under Amgen’s 2009 Equity Incentive Plan. These dividend equivalents are credited to his unvested restricted stock units and will be paid out in Amgen common shares on a one-for-one basis as the underlying awards vest, with cash paid for any remaining fractional share amounts.

Insider Trade Summary

Grant/Award: 12,063 shares

Grant/Award 1 txn

Insider Griffith Peter H.

Role EVP & CFO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	12,063	$0.00	$0.00

Holdings After Transaction: Common Stock — 54,587 shares (Direct)

Footnotes (1)

1. F1. These shares include 676 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Amgen (AMGN) report for CFO Peter H. Griffith?

Amgen’s CFO Peter H. Griffith reported an equity award of 12,063 shares of common stock. The award was recorded on a Form 4 as a grant acquisition at no cash price, increasing his directly held ownership to 54,587 Amgen shares after the transaction.

How many Amgen (AMGN) shares does the CFO own after this Form 4 transaction?

After the reported grant, CFO Peter H. Griffith directly holds 54,587 shares of Amgen common stock. This figure reflects the addition of 12,063 granted shares disclosed in the filing and represents his direct ownership position following the award transaction.

Was the Amgen (AMGN) CFO’s 12,063-share award a market purchase or a grant?

The 12,063 Amgen shares reported by CFO Peter H. Griffith were acquired as a grant or award transaction, not a market purchase. The Form 4 lists the shares at a per-share price of $0.0000, indicating an equity compensation grant rather than an open-market buy.

What are the 676 dividend equivalents mentioned in the Amgen (AMGN) Form 4 footnote?

The filing notes 676 dividend equivalents credited to the CFO’s unvested restricted stock units under Amgen’s 2009 Equity Incentive Plan. These units convert into Amgen common shares on a one-to-one basis as the RSUs vest, with cash paid for any remaining fractional share amount.

How are Amgen (AMGN) dividend equivalents on RSUs paid to the CFO?

Dividend equivalents on the CFO’s unvested Amgen RSUs are paid in common shares and cash. The Form 4 explains they convert one-for-one into Amgen shares following the RSU vesting schedule, with any remaining fractional share value settled through a separate cash payment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 08:37 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Griffith Peter H.

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CA 91320

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & CFO

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		A		12,063	A	$0	54,587(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares include 676 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ Peter H. Griffith	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.